Actinium Pharmaceuticals has been granted a patent for new bifunctional chelators used in creating radiolabeled targeting agents for cancer therapy or diagnosis. The patent includes conjugates of the chelators with cancer antigen targeting agents. GlobalData’s report on Actinium Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Actinium Pharmaceuticals Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Actinium Pharmaceuticals, Antibody drug conjugates(ADC) cancer therapy was a key innovation area identified from patents. Actinium Pharmaceuticals's grant share as of April 2024 was 27%. Grant share is based on the ratio of number of grants to total number of patents.

Bifunctional chelators for radiolabeled cancer antigen targeting agents

Source: United States Patent and Trademark Office (USPTO). Credit: Actinium Pharmaceuticals Inc

A recently granted patent (Publication Number: US11964948B2) discloses a novel bifunctional chelator compound designed for use in medical imaging and therapy applications. The compound comprises a formula R—L1—M, where R is a reactive group and L1 includes various components. The chelator compound can be conjugated with molecules containing primary amine or free thiol groups, such as peptides, proteins, antibodies, and antibody fragments, expanding its potential applications in targeted therapy and diagnostics. Additionally, the chelator compound can chelate a variety of radionuclides, including 134Ce, 43Sc, 44Sc, and others, enhancing its versatility in medical imaging and treatment.

Furthermore, the patent describes methods for manufacturing chelator-conjugated molecules using the bifunctional chelator compound. These methods involve reacting the compound with molecules containing primary amine or free thiol groups, followed by chelating a radionuclide to the resulting conjugate. The flexibility of these methods allows for the creation of a wide range of chelator-conjugated molecules suitable for various medical applications, including cancer imaging and therapy. Overall, the patent highlights the potential of the disclosed bifunctional chelator compound and associated manufacturing methods in advancing precision medicine and personalized healthcare.

To know more about GlobalData’s detailed insights on Actinium Pharmaceuticals, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies